Fore Biotherapeutics
Fore Biotherapeutics is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The company's mission is to create targeted therapies for unaddressed tumor mutations, leveraging proprietary platforms and clinical development of assets like plixorafenib, a BRAF inhibitor. They focus on delivering high-quality, innovative cancer treatments with a patient-first approach, emphasizing science, focus, excellence, and compassion.
Industries
Nr. of Employees
small (1-50)
Fore Biotherapeutics
Fore Bio, 3675 Market Street, Suite 200, Philadelphia, PA 19104
Patents
Methods and systems for determining oncogenic index of patient specific mutations
US-11015229-B2
View Details
Methods and systems for determining oncogenic index of patient specific mutations
US-11015229-B2
View DetailsProducts
Next-generation orally available selective BRAF inhibitor (lead clinical asset)
An investigational small-molecule, orally administered selective inhibitor designed to target a broad range of BRAF alterations (V600 and non-V600, including class 2 mutants and fusions) while minimizing paradoxical MAPK pathway activation. Evaluated as single-agent and in combination, with clinical data from Phase 1/2a and ongoing Phase 2 master-protocol studies.
Next-generation orally available selective BRAF inhibitor (lead clinical asset)
An investigational small-molecule, orally administered selective inhibitor designed to target a broad range of BRAF alterations (V600 and non-V600, including class 2 mutants and fusions) while minimizing paradoxical MAPK pathway activation. Evaluated as single-agent and in combination, with clinical data from Phase 1/2a and ongoing Phase 2 master-protocol studies.
Services
Sourcing and in-licensing clinical-stage compounds and structuring collaborative development agreements to advance targeted oncology assets into clinical development for hyper-targeted patient populations.
Physician-initiated process to request investigational product access for individual patients who are not eligible for clinical trials, with defined eligibility criteria, documentation requirements and a typical response timeframe.
Design and operational management of multi-center clinical studies, including master-protocol Phase 2 studies, dose optimization, safety monitoring and biomarker-driven enrollment.
Sourcing and in-licensing clinical-stage compounds and structuring collaborative development agreements to advance targeted oncology assets into clinical development for hyper-targeted patient populations.
Physician-initiated process to request investigational product access for individual patients who are not eligible for clinical trials, with defined eligibility criteria, documentation requirements and a typical response timeframe.
Design and operational management of multi-center clinical studies, including master-protocol Phase 2 studies, dose optimization, safety monitoring and biomarker-driven enrollment.
Expertise Areas
- Precision oncology and hyper-targeted therapies
- Clinical trial management (Phase 1/2 and registrational Phase 2)
- Functional genomics and translational discovery
- Biomarker development and ctDNA monitoring
Key Technologies
- Functional genomics screening
- Machine learning–driven drug discovery
- Next-generation BRAF inhibitor design (paradox-breaker approach)
- ctDNA-based biomarker monitoring